Previous 10 | Next 10 |
2024-01-16 17:30:34 ET More on Natera Natera: Squeezing The Last Drop From NIPT Growth Engine Natera, Inc. (NTRA) Q3 2023 Earnings Call Transcript Natera, Inc. 2023 Q3 - Results - Earnings Call Presentation Natera raises FY23 revenue guidance by $20M to $1.07...
No willful infringement, damages significantly less than what Ravgen was seeking Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that a jury has reached a verdict in the United States District Court for the Western District of Texas regarding a p...
2024-01-16 11:49:56 ET More on iShares Russell 1000 Growth ETF: IWF: Price Isn't Everything; Favor Growth Over Value Citi’s 30 stocks for its 2024 top themes Top overweight stocks with high growth and low volume - MS Seeking Alpha’s Quant Rating...
Shares of Natera, Inc. (NASDAQ: NTRA) traded at a new 52-week high today and are currently trading at $37.53. So far today, approximately 1.19M shares have been exchanged, as compared to an average 30-day volume of 1.17M shares. Natera, Inc., a diagnostics company, develops and commercializes...
2024-01-09 07:23:52 ET More on Natera Natera: Squeezing The Last Drop From NIPT Growth Engine Natera, Inc. (NTRA) Q3 2023 Earnings Call Transcript Natera, Inc. 2023 Q3 - Results - Earnings Call Presentation Natera wins court order barring NeoGenomics from sel...
2023 revenues are expected to be approximately $20 million above top end of guidance Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced preliminary revenue results for the fourth quarter and full year ended Dec. 31, 2023. The Company expec...
2024-01-08 08:31:52 ET Summary The healthcare sector was flat in 2023 year as a result of some unique issues. Drug price regulation will be a serious challenge for the sector this year. Defensive healthcare industry groups should do well during the first half and biotechnology...
2024-01-07 17:18:52 ET More on Akoya Biosciences, Exact Sciences, etc. Guardant Health: Vast Market Opportunity, Challenging Valuation Illumina: The Divestiture Of Grail Could Unlock Significant Shareholder Value Illumina: Conditions Are Met For A Rebound Nan...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will participate in the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, Jan. 9, 2024 at 3:45 p.m. PT (6:45 p.m. ET). Members of Natera’s management will deliver a...
2023-12-28 14:52:16 ET More on NeoGenomics NeoGenomics, Inc. 2023 Q3 - Results - Earnings Call Presentation NeoGenomics, Inc (NEO) Q3 2023 Earnings Call Transcript NeoGenomics: Short-Term Upsides Possible, Long-Term Not Supported By Economic Value Natera wins...
News, Short Squeeze, Breakout and More Instantly...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that members of its leadership team will present at the Canaccord Genuity 44th Annual Growth Conference on Wednesday, Aug. 14 at 12:30 pm ET | 9:30 am PT in Boston, MA. A live webcast and audio archive of...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its second quarter ended June 30, 2024, after the market close on Aug. 8, 2024. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET...
Study reports high accuracy of Signatera for surveillance of MCC patients, suggests potential to reduce frequency of surveillance imaging Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in the Journal of Clinical Oncolog...